This study investigated the curative effect of cryoablation combined with molecular target therapy for advanced non-small cell lung cancer (NSCLC). Thirty-six female patients with NSCLC and epidermal growth factor receptor gene mutations were randomly divided into two groups: 18 patients received the molecular target therapy gefitinib (group I), an epidermal growth factor receptor-tyrosine kinase inhibitor; and 18 patients were treated with cryoablation prior to the administration of gefitinib (group II).
Treatment with gefitinib was continued for 6 months. Compared with group I, the rates of partial regression, stabilization of disease and progression of disease were improved in group II at the end of the 6 months of gefitinib treatment. Moreover, the 1-year survival rate in group II was significantly higher than that in group I. This suggests that cryoablation therapy combined with gefitinib could improve the effects of treatment and the prognosis of patients with advanced NSCLC.
SasakiHEndoKOkudaK: Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol2008; 134: 569–577.
2.
D'AddarioGRauchDStuppR: Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol2008; 19: 739–745.
3.
AsahinaHYamazakiKKinoshitaI: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer2006; 95: 998–1004.
4.
SequistLVMartinsRGSpigelD: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol2008; 26: 2442–2449.
5.
NihoSKubotaKGotoK: First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: A phase II study. J Clin Oncol2006; 24: 64–69.
6.
LeeDHHanJYKimHT: Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer2006; 53: 339–345.
ElliottBACurryTBAtwellTD: Lung isolation, one-lung ventilation, and continuous positive airway pressure with air for radiofrequency ablation of neoplastic pulmonary lesions. Anesth Analg2006; 103: 463–464.
9.
LeeSMWonJYLeeDY: Percutaneous cryoablation of small hepatocellular carcinomas using a 17-gauge ultrathin probe. Clin Radiol2011; 66: 752–759.
10.
SharmaAMooreWHLanutiM: How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging2011; 26: 162–174.
11.
TherassePArbuckSGEisenhauerEA: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst2000; 92: 205–216.
12.
El-ZammarOAZhangSKatzensteinAL: Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. Diagn Mol Pathol2009; 18: 133–137.
13.
GoldstrawPCrowleyJChanskyKInternational Association for the Study of Lung Cancer International Staging Committee (IASCL): The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol2007; 2: 706–714.
14.
OkenMMCreechRHTormeyDC: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982; 5: 649–655.
15.
ChenWZhangSZouX: Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi2010; 13: 488–493 [in Chinese, English abstract].
16.
MoriKKobayashiHKamiyamaY: A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol2009; 64: 73–78.
17.
FoxJFordERedmondK: Quantification of tumor volume changes during radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys2009; 74: 341–348.
18.
Dehing-OberijeCYuSDe RuysscherD: Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys2009; 74: 355–362.
19.
DyGKHillmanSLRowlandKMJr: A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer2010; 116: 5686–5693.
LieCHChangHCChaoTY: First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan. Clin Lung Cancer2011; 12: 116–124.
22.
KeedyVLTeminSSomerfieldMR: American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol2011; 29: 2121–2127.
23.
MuXLLiLYZhangXT: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res2005; 11: 4289–4294.
24.
LiCSunYFangZ: Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. J Thorac Oncol2011; 6: 1016–1021.
25.
YanoSWangWLiQ: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res2008; 68: 9479–9487.
26.
UramotoHSugioKOyamaT: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer2006; 51: 71–77.
27.
WongASSoongRSeahSB: Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol2008; 3: 400–404.
SimSHHanSWOhDY: Erlotinib after gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer2009; 65: 204–207.
30.
YangCHShihJYChenKC: Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer2006; 107: 1873–1882.
31.
LinWCChiuCHLiouJL: Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer2006; 54: 193–199.
32.
Van LaethemJL: Adjuvant treatment for colorectal cancer. Acta Gastroenterol Belg2001; 64: 263–267.
33.
SturmJWKeeseMABonninghoffRG: Locally ablative therapies of hepatocellular carcinoma. Onkologie2001; 24 (5 suppl): 35S–45S [in German, English abstract].
34.
OkumaTMatsuokaTHamamotoS: Percutaneous computed tomography-guided radiofrequency ablation of lung tumors complicated with idiopathic interstitial pneumonia. Ann Thorac Surg2009; 87: 948–950.
35.
PaddaSKotharyNDoningtonJ: Complications of ablative therapies in lung cancer. Clin Lung Cancer2008; 9: 122–126.
36.
MaiwandMOEvansJMBeesonJE: The application of cryosurgery in the treatment of lung cancer. Cryobiology2004; 48: 55–61.
37.
FolkmanJBrowderTPalmbladJ: Angiogenesis research: guideline for translation to clinical application. Thromb Haemost2001; 86: 23–33.
38.
FacciabeneAPengXHagemannIS: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature2011; 475: 226–230.
39.
AndersenSDonnemTAl SaadS: Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol2009; 4: 463–471.
40.
SanoIHaraSMatsumotoK: Clinical analysis of resected pulmonary pleomorphic carcinoma. Kyobu Geka2009; 62: 187–191 [in Japanese, English abstract].
LindJSHerderGJSmitEF: New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis. Ned Tijdschr Geneeskd2008; 152: 928–932 [in Dutch, English abstract].
43.
KimuraMRabbaniZMouravievV: Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and microvessel density. Cryobiology2010; 61: 148–154.
44.
AsimakopoulosGBeesonJEvansJ: Cryosurgery for malignant endobronchial tumors: analysis of outcome. Chest2005; 127: 2007–2014.
